Skip to Content

Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C News

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

FDA Approves Sovaldi (sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older

Posted 8 Apr 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indications for Sovaldi (sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic HCV infection, in combination with ribavirin. There are an estimated 23,000-46,000 pediatric HCV patients in the United States, most of whom were infected with the virus at birth. Sovaldi has a boxed warning in their respective product labels regarding the risk of hepatitis B virus reactivation in HCV/HBV co-infected patients. See below for important safety information. Sovaldi for Pediatric Patients The ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

FDA Approves Harvoni (ledipasvir and sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older

Posted 8 Apr 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved asupplemental indication for Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. Harvoni was approved for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection. There are an estimated 23,000-46,000 pediatric HCV patients in the United States, most of whom were infected with the virus at birth. Harvoni has a boxed warning in its product label regarding the risk of hepatitis B virus reactivation in HCV/HBV co-infected patients. See below for important safety information. Harvoni for Pediatric Patients The supplemental new drug ... Read more

Related support groups: Hepatitis C, Harvoni, Ledipasvir/sofosbuvir

FDA Approves Two Hepatitis C Drugs - Sovaldi and Harvoni - for Pediatric Patients

Posted 7 Apr 2017 by Drugs.com

April 7, 2017 – The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing the virus from multiplying, and in most cases, they cure HCV. “These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Today’s approvals provide pediatric treatment options for six major genotypes, or strains, of HCV. Harvoni is in ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Sofosbuvir, Ledipasvir/sofosbuvir

FDA Approves Hep C Drugs for Kids 12 and Older

Posted 7 Apr 2017 by Drugs.com

FRIDAY, April 7, 2017 – The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C infection in children aged 12 and older. Both Solvaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are already approved for use in adults, the agency said in a news release Friday. The medications are antivirals that prevent the hepatitis C virus (HCV) from reproducing. "In most cases, they cure HCV," the FDA added. "These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," said Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. Hepatitis C causes liver inflammation that can lead to liver failure. Between 3 and 4 million people in the United States are infected with the virus, the agency said. Children born to infected mothers are at higher risk ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

Hepatitis Infection May Raise Risk for Parkinson's Disease

Posted 30 Mar 2017 by Drugs.com

THURSDAY, March 30, 2017 – People with the liver infection hepatitis may be at heightened risk of developing Parkinson's disease, a large new study suggests. The study, published online March 29 in Neurology, is the second in the past year to link hepatitis to Parkinson's. Specifically, the new study found that people who'd been infected with hepatitis B or C were 51 percent to 76 percent more likely to develop Parkinson's, compared to people who'd never had hepatitis. The researchers don't know why the connection exists. And the study cannot prove a cause-and-effect link. But the association between Parkinson's disease and hepatitis appears to be "strong," according to Dr. Michael Okun, national medical director of the Parkinson's Foundation. Last year, a study in Taiwan found that people with hepatitis C faced an increased risk of Parkinson's. Now the new findings, based on millions ... Read more

Related support groups: Hepatitis C, Parkinson's Disease, Hepatitis B, Parkinsonian Tremor, Parkinsonism, Exposure to Hepatitis B Virus

Better Efforts Could Help Rid the U.S. of Hepatitis B, C: Report

Posted 28 Mar 2017 by Drugs.com

TUESDAY, March 28, 2017 – Improved prevention, screening and treatment could help eliminate hepatitis B and C as serious public health problems in the United States and save nearly 90,000 lives by 2030, according to a new report. About 1.3 million people in the United States have chronic hepatitis B and about 2.7 million have chronic hepatitis C. These infections cause about 80 percent of liver cancer cases worldwide. Liver cancer incidence in the United States rose 38 percent between 2003 and 2012. Liver cancer deaths increased 56 percent during that time, primarily due to viral hepatitis, according to the report from the National Academies of Sciences, Engineering, and Medicine. "Viral hepatitis is simply not a sufficient priority in the United States," said report committee chair Dr. Brian Strom, chancellor and professor at Rutgers University Biomedical and Health Sciences in ... Read more

Related support groups: Hepatitis C, Hepatitis B, Hepatitis B Adult Vaccine, Twinrix, Hepatitis B Prevention, Exposure to Hepatitis B Virus, Engerix-B, Vaccination and Prophlaxis, Hepatitis B Prophylaxis, Hepatitis A Adult Vaccine/hepatitis B Adult Vaccine

New Hepatitis C Drugs Might Eliminate the Disease

Posted 20 Mar 2017 by Drugs.com

MONDAY, March 20, 2017 – Newer treatments for hepatitis C appear to eliminate the virus in the vast majority of those taking oral antiviral medications, raising the hope that this disease might someday be eradicated in the United States. The oral medications "work really well in most patients that have hepatitis C," said Dr. Oluwaseun Falade-Nwulia, the study's lead author. She's an assistant professor of medicine at Johns Hopkins University School of Medicine in Baltimore. Most people have a 95 percent chance of being cured, meaning the hepatitis C virus is no longer detectable in a person's bloodstream, the finding showed. "The other big message is that these therapies are very safe. The risk of side effects are very low," she said. Plus, many patients can be treated in just 12 weeks, according to the study published online March 20 in the Annals of Internal Medicine. "It's ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Ribavirin, Epclusa, Sofosbuvir, Copegus, Ribasphere, Interferon Alfa-2B/Ribavirin, Ledipasvir/sofosbuvir, Interferon Alfa-2A, Rebetol, Rebetron, RibaPak, Olysio, Virazole, Roferon-A, Sofosbuvir/velpatasvir, RibaTab, Moderiba

Baby Boomers Get an 'F' for Hep C Testing

Posted 8 Mar 2017 by Drugs.com

WEDNESDAY, March 8, 2017 – Despite recommendations, too few American baby boomers are tested for hepatitis C, a new study reveals. In 2013, the U.S. Preventive Services Task Force (USPSTF) advised all Americans born between 1945 and 1965 to get a one-time test for hepatitis C virus. "Prevalence of [hepatitis C virus] testing among baby boomers did not substantially increase and remains low two years after the USPSTF recommendation in 2013," Ahmedin Jemal of the American Cancer Society's surveillance and health services research program, and colleagues reported. Of the estimated 3.5 million Americans who have the virus, 80 percent are baby boomers. And most don't know they are infected with the contagious liver disease, the researchers explained. Treatment is needed to reduce the risk of related diseases, such as chronic hepatitis, cirrhosis and liver cancer, the study authors added. ... Read more

Related support groups: Hepatitis C, Sexually Transmitted Diseases, Blood Transfusion, Blood Cell Transplantation

Prison Time Can Be Deadly … to Health

Posted 26 Feb 2017 by Drugs.com

FRIDAY, Feb. 24, 2017 – Prison time can exact a deadly toll on health, new research suggests. Being behind bars puts people at greater risk for both developing certain types of cancer and dying from their disease, Canadian researchers found. "We know that people who spend time in jails and prisons in Canada are more likely to use alcohol and tobacco, as well as have infections such as HPV (human papillomavirus) and HIV, which can increase the risk of developing some types of cancer," said study author Dr. Fiona Kouyoumdjian. She is a researcher at St. Michael's Hospital and McMaster University in Toronto. For the study, the researchers followed nearly 50,000 people sentenced to jail time in Ontario in 2000. Specifically, the investigators examined how many of these inmates developed cancer and how many died from the disease over the course of 12 years. By 2012, 2.6 percent of the men ... Read more

Related support groups: Infections, Cancer, Hepatitis C, Smoking, Smoking Cessation, Sexually Transmitted Diseases, Colorectal Cancer, Human Papilloma Virus, Cervical Cancer, Viral Infection

Cancer Isn't 'One Size Fits All' for Hispanics

Posted 21 Feb 2017 by Drugs.com

TUESDAY, Feb. 21, 2017 – Cancer death rates can vary widely between different Hispanic ethnic groups in the United States, a new study finds. "Hispanic populations are all different, reflecting their country of origin, cultural experiences and socioeconomic status," said study author Dr. Paulo Pinheiro, an associate professor of epidemiology at the University of Nevada, Las Vegas. "If we can detect the differences among them, we can more easily identify public health strategies that could decrease their cancer risk and improve health outcomes," he explained. In the study, Pinheiro's team analyzed 2008-2012 health data from Florida. The researchers said this is the only state with statistically significant representation from all major Hispanic ethnic groups: Cuban, Puerto Rican, Mexican, Central American, Dominican and South American. While cancer is the leading cause of death among ... Read more

Related support groups: Cancer, Hepatitis C, Prostate Cancer, Hepatocellular Carcinoma, Hepatic Tumor

Newer Hepatitis C Drugs May Pose Health Risks: Study

Posted 25 Jan 2017 by Drugs.com

Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported. Two of the drugs, Sovaldi and Harvoni, are so-called blockbusters made by Gilead Sciences and priced at $1,000 a pill. Sovaldi was approved in 2013 and Harvoni in 2014. These and other antiviral drugs can cure hepatitis C in 12 weeks in many patients. The number of adverse events is fairly small and the findings are not conclusive, but experts say the study published online Wednesday should serve as a warning, The Times reported. The study said ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Ribavirin, Incivek, Epclusa, Victrelis, Sofosbuvir, Liver and Pancreatic Disease, Copegus, Ribasphere, Telaprevir, Boceprevir, Interferon Alfa-2B/Ribavirin, Rebetol, Ledipasvir/sofosbuvir, Olysio, Rebetron, RibaPak, Simeprevir

Rising Price of Opioid OD Antidote Could Cost Lives: Study

Posted 8 Dec 2016 by Drugs.com

WEDNESDAY, Dec. 7, 2016 – Escalating prices of the drug naloxone may threaten efforts to reduce opioid-related deaths across America, a team from Yale University and the Mayo Clinic warns. Naloxone is a drug given to people who overdose on prescription opioids and heroin. If administered in time, it can reverse the toxic and potentially deadly effects of "opioid intoxication." The research team called attention to skyrocketing prices for the lifesaving antidote, noting: Hospira (a Pfizer Inc. company) charges $142 for a 10-pack of naloxone – up 129 percent since 2012. Amphastar's 1 milligram version of naloxone is used off-label as a nasal spray. It's priced around $40 – a 95 percent increase since September 2014. Newer, easier-to-use formulations are even more expensive – a two-dose package of Evzio (naloxone) costs $4,500, an increase of more than 500 percent over two years. ... Read more

Related support groups: Suboxone, Opiate Dependence, Opiate Withdrawal, Hepatitis C, Drug Dependence, Epinephrine, Talwin Nx, EpiPen, Adrenalin, Zubsolv, Primatene Mist, Naloxone, Septocaine, Opiate Adjunct, Toxic Reactions Incl Drug and Substance Abuse, Bunavail, Buprenorphine/Naloxone, Naloxone/Pentazocine, EpiPen 2-Pak, Bupivacaine/Epinephrine

Use of Needle Exchange Programs Up Dramatically in 10 Years: CDC

Posted 30 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 30, 2016 – Although there was a significant increase in the use of syringe services programs (SSPs) – more commonly known as needle exchange programs – across the United States over the past decade, many injection drug users don't always use sterile needles, a federal government report says. Previously used needles put drug users at risk for infectious diseases such as HIV and hepatitis B and C, the report noted. Needle exchange programs provide sterile needles and syringes to injection drug users. These programs also refer drug users to prevention, care and treatment services. Researchers from the U.S. Centers for Disease Control and Prevention looked at data from injection drug users in 22 cities with high rates of HIV. In 2015, 54 percent of injection drug users said they used a needle exchange program in the past year. That was up significantly compared to the 36 ... Read more

Related support groups: Opiate Dependence, Hepatitis C, HIV Infection, Drug Dependence, Hepatitis B, Pre-Exposure Prophylaxis, Substance Abuse, Toxic Reactions Incl Drug and Substance Abuse, Hepatitis B Prevention, Exposure to Hepatitis B Virus, Hepatitis B Prophylaxis

Robotic Surgical Tools Tough to Keep Clean

Posted 1 Nov 2016 by Drugs.com

TUESDAY, Nov. 1, 2016 – Even with repeated cleanings, it's virtually impossible to remove all contamination from robotic surgical instruments, a new study suggests. "One of the top priorities for hospitals is to treat patients safely and with minimal risk of infection," said study author Yuhei Saito, an assistant professor at the University of Tokyo Hospital in Japan. "Our results show that surgical instruments could be placing patients at risk due to current cleaning procedures. One way to address this issue is to establish new standards for cleaning surgical instruments, including multi-part robotic tools," Saito said in a news release from the Society for Healthcare Epidemiology of America. Over the course of 21 months, the researchers assessed protein residue on 132 robotic and standard surgical instruments that were cleaned according to manufacturers' instructions. The cleanings ... Read more

Related support groups: Infections, Surgery, Bacterial Infection, Hepatitis C, Hepatitis B, Hepatitis A, Surgical Prophylaxis, Gastrointestinal Surgery, Cardiothoracic Surgery

FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Posted 10 Oct 2016 by Drugs.com

ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks. As a result, FDA is requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation to be added to the drug labels of these DAAs directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment. This warning will also be included in the patient information leaflet or Medication Guides for these medicines. BACKGROUND: Direct-acting antiviral medicines are used to treat chronic hepatitis C virus (HCV) ... Read more

Related support groups: Hepatitis C, Harvoni, Hepatitis B, Sovaldi, Epclusa, Zepatier, Sofosbuvir, Viekira Pak, Daklinza, Ledipasvir/sofosbuvir, Daclatasvir, Olysio, Simeprevir, Viekira XR, Technivie, Ombitasvir/paritaprevir/ritonavir, Sofosbuvir/velpatasvir, Elbasvir/grazoprevir, Dasabuvir/ombitasvir/paritaprevir/ritonavir

Page 1 2 3 4 5 6 7 8 9 10 Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Harvoni, Sovaldi, ribavirin, Incivek, Pegasys, Epclusa, Zepatier, Victrelis, sofosbuvir, view more... PegIntron, Viekira Pak, Daklinza, Ribasphere, interferon alfa-2b, Copegus, telaprevir, boceprevir, Rebetol, interferon alfa-2a, interferon alfa-2b / ribavirin, ledipasvir / sofosbuvir, Olysio, Rebetron, Intron A, peginterferon alfa-2b, daclatasvir, RibaPak, Roferon-A, Viekira XR, peginterferon alfa-2a, Technivie, ombitasvir / paritaprevir / ritonavir, simeprevir, Moderiba, RibaTab, sofosbuvir / velpatasvir, Infergen, elbasvir / grazoprevir, dasabuvir / ombitasvir / paritaprevir / ritonavir, interferon alfacon-1